Report cover image

Strategic Intelligence: Precision and Personalized Medicine - Advanced Therapeutics

Publisher GlobalData
Published Feb 27, 2026
Length 60 Pages
SKU # GBDT21015607

Description

Strategic Intelligence: Precision and Personalized Medicine - Advanced Therapeutics

Summary

Precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.

Gene-modified cell therapies are emerging as a cornerstone modality within PPM.

Cell therapies are entering a rapid growth phase across oncology and regenerative medicine.

Gene therapy remains a blockbuster-led modality with expanding therapeutic reach.

Antisense oligonucleotides are emerging as a fast-growing modality within PPM.

Oncolytic virus therapies show emerging commercial traction but remain a niche modality.

Core precision medicine enablers are strengthening adoption.

Scope
  • This report talks about how precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.
  • Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.

Table of Contents

60 Pages
  • Executive Summary
  • Introduction
    • Milestones in Precision Medicine: 2015-25
    • Gene-Modified Cell Therapies Are Forecast to Generate the Highest Sales by 2031
    • Asia-Pacific Drives 56% of Global Clinical Trials vs. 22% in North America and 19% in Europe
    • Oncology Dominates Pipeline Activity Across Precision Medicine Modalities
    • Gene-Modified Cell Therapy Pipeline by Therapy Area and Stage of Development
    • Carvykti Forecast to Be the Primary Revenue Driver in Gene- Modified Cell Therapies
    • Kymriah and Abecma Sales Flatten as Newer High-Efficacy Therapies Enter the Market
    • Top Five Forecasted Drugs by 2031 for Gene-Modified Cell Therapies
    • CD19 Emerges as the Leading MOA Among Gene-Modified Cell Therapy Top Sellers
    • Cell Therapy Pipeline By Therapy Area And Stage Of Development
    • Amtagvi and Next-Gen Platforms to Drive $3.4B Cell Therapy Market by 2031
    • Three Cell Therapies Have Dropped from the Top Five Due to Niche Population, Challenges in LCM, and Market Exit
    • Top Five Forecast Drugs by 2031 for Cell Therapies
    • Iovance Is Well Positioned to Become a TIL Therapy Leader
    • Gene Therapy Pipeline by Therapy Area and Stage of Development
    • Zolgensma, the Billion-dollar Blockbuster in the Gene Therapy Market
    • Challenges Remain with Gene Therapies with Efficacy & Safety Issues
    • Top Five Forecasted Drugs by 2031 for Gene Therapies
    • Vyjuvek and Novel Administration Unlocking Gene Therapy Uptake
    • ASO Pipeline by Therapy Area and Stage of Development
    • Wainua to Lead Growth in Rapidly Expanding ASO Market by 2031
    • DMD dropped out of the top selling ASO's in 2025
    • Top Five Forecasted ASO Drugs by 2031
    • Leading Companies with ASOs: Marketed & Late-Stage Portfolio Strength by Top Five Drugs
    • Oncolytic Virus Pipeline by Therapy Area and Stage of Development
    • Top Five Forecasted Drugs by 2031 for Oncolytic Viruses
    • Late-Stage Innovation Faces Commercial Headwinds in Oncolytic Viruses
    • Case Studies Demonstrating Success Clinically and Commercially
    • CGTs Will Continue to Be the Cornerstone to PPM
    • Genomics: a Key Enabler of PPM Advancement
    • Biomarkers Are the Engine of Precision for Advanced Therapies
    • Gene-Modified Cell Therapy Biomarkers
    • Cell Therapy Biomarkers
    • Gene Therapy Biomarkers
    • ASO Biomarkers
    • Oncolytic Virus Biomarkers
  • Key Takeaways
    • Abbreviations
    • Related Reports

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us